A team of electrical engineers, computer scientists, and biomedical engineers at the University of California-Irvine report that they have created a new lab-on-a-chip that can help study tumor heterogeneity to reduce resistance to cancer therapies. The researchers combined artificial intelligence, microfluidics, and nanoparticle inkjet printing in a device that enables the examination and…
Nanostics and Protean partner to offer CDX Prostate risk score as a diagnostic tool to men suspected of having aggressive prostate cancer in the USA.
Nanostics and Protean partner to offer CDX Prostate risk score as a diagnostic tool to men suspected of having aggressive prostate cancer in the USA.
Dr. Tony Magliocco of the Moffit Cancer Center joins us to discuss the indepensible role of pathologists in precision medicine and the importance of technology…
Anthony Magliocco, MD is a cancer expert with over 30 years of experience.In this video he explains why someone might be diagnosed with a ‘cancer…
Protean and Roche have created a novel project to accelerate access to precision oncology for community based oncology programs.
New research suggests stars in the Milky Way give off infrared heat expected from Dyson spheres, which physicist Freeman Dyson theorized could be created by…
Cancer Informant is a podcast made to inform cancer patients and their loved ones about their options for cancer testing and treatment. Dr. Tony Magliocco…
Learn more about how prostate cancer is detected, risk factors, and treatments on our full video. Watch the full video on prostate cancer by clicking…
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
Aventa Genomics, a joint venture of Arima Genomics and Protean BioDiagnostics, launched the Aventa FusionPlus test for patients with solid cancers.
